Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05208931
Other study ID # 1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2021
Est. completion date September 1, 2022

Study information

Verified date April 2023
Source The S.N. Fyodorov Eye Microsurgery State Institution
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study involves the development of an algorithm for predicting anatomical and functional results of therapy with angiogenesis inhibitors in patients with retinal pigment epithelium detachments in neovascular age-related macular degeneration, based on primary optical coherence tomography of the macular zone and clinical data.


Description:

Patients were divided into 3 groups according to the results of therapy: adhesion of detachment, lack of adherence to detachment, rupture of detachment. For these groups, OCT images of the macular zone with maximum detachment before therapy are selected. These images, along with other clinical parameters, are input to the algorithm. The result is one of the 3 treatment outcomes listed above. The methods that will be used to develop the algorithm include methods for processing and transforming data, deep machine learning, metrics for calculating the accuracy of algorithms.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date September 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion criteria: - Linear B - scan through the macular area with the longest detachment - Other pathologies Exclusion criteria: - Images without detachment - Images on which it is possible to diagnose the need for therapy only in the presence of additional factors not considered in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Anti-vascular endothelial growth factor therapy
0.05 ml anti-VEGF, intravitreal, monthly

Locations

Country Name City State
Russian Federation The S.N. Fyodorov Eye Microsurgery State Institution Krasnodar

Sponsors (1)

Lead Sponsor Collaborator
The S.N. Fyodorov Eye Microsurgery State Institution

Country where clinical trial is conducted

Russian Federation, 

References & Publications (6)

Bogunovic H, Montuoro A, Baratsits M, Karantonis MG, Waldstein SM, Schlanitz F, Schmidt-Erfurth U. Machine Learning of the Progression of Intermediate Age-Related Macular Degeneration Based on OCT Imaging. Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO141-BIO150. doi: 10.1167/iovs.17-21789. — View Citation

Kozina, E. V., S. N. Sakhnov, V. V. Myasnikova, E. V. Bykova, and L. E. Aksenova. 2021. 'Modern Trends in Diagnostics and Prediction of Results of Anti-Vascular Endothelial Growth Factor Therapy of Pigment Epithelial Detachment in Neovascular Agerelated Macular Degeneration Using Deep Machine Learning Method (Literature Review)'. Acta Biomedica Scientifica 6 (6-1): 190-203. https://doi.org/10.29413/ABS.2021-6.6-1.22.

Prahs P, Radeck V, Mayer C, Cvetkov Y, Cvetkova N, Helbig H, Marker D. OCT-based deep learning algorithm for the evaluation of treatment indication with anti-vascular endothelial growth factor medications. Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):91-98. doi: 10.1007/s00417-017-3839-y. Epub 2017 Nov 10. — View Citation

Rohm M, Tresp V, Muller M, Kern C, Manakov I, Weiss M, Sim DA, Priglinger S, Keane PA, Kortuem K. Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018 Jul;125(7):1028-1036. doi: 10.1016/j.ophtha.2017.12.034. Epub 2018 Feb 14. — View Citation

Schmidt-Erfurth U, Bogunovic H, Sadeghipour A, Schlegl T, Langs G, Gerendas BS, Osborne A, Waldstein SM. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2018 Jan;2(1):24-30. doi: 10.1016/j.oret.2017.03.015. Epub 2017 May 31. — View Citation

Schmidt-Erfurth U, Waldstein SM, Klimscha S, Sadeghipour A, Hu X, Gerendas BS, Osborne A, Bogunovic H. Prediction of Individual Disease Conversion in Early AMD Using Artificial Intelligence. Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3199-3208. doi: 10.1167/iovs.18-24106. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prediction algorithm Neural network classifier 1.09.2022
See also
  Status Clinical Trial Phase
Recruiting NCT04101877 - The Sahlgrenska Anti-VEGF Study Phase 2
Completed NCT03953079 - A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Phase 2
Terminated NCT03577899 - Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Completed NCT01926977 - Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration Phase 1/Phase 2
Recruiting NCT00370539 - Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD Phase 3
Recruiting NCT03683251 - Extension Study for the Port Delivery System With Ranibizumab (Portal) Phase 3
Completed NCT03909425 - Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography
Completed NCT03744767 - Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration Phase 2
Recruiting NCT04690556 - Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD Phase 3
Completed NCT05281042 - Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
Completed NCT03677934 - A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration Phase 3
Recruiting NCT03594461 - Intense Treatment Regimen With Intravitreal Aflibercept Injection Phase 1/Phase 2
Completed NCT05131646 - Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
Completed NCT04537884 - Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration Phase 1
Completed NCT03216538 - Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Completed NCT04304755 - Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) Phase 2
Completed NCT01958918 - Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Phase 4
Active, not recruiting NCT01918878 - Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Phase 4
Completed NCT01712035 - Neovascular Age-related Macular Degeneration